Class / Patent application number | Description | Number of patent applications / Date published |
514800500 | Insulin-like growth factor (IGF) or derivative | 65 |
20100267633 | N-(4-Oxo-3,4-Dihydroquinazolin-2Yl) Butanamides as Androgen Receptor Modulators - The invention relates to substituted N-(4-oxo-3,4-dihydroquinazolin-2-yl)butanamid derivatives which modulate androgen receptors to treat conditions such as: osteoporosis, peridontal disease, bone fracture, frailty, and sarcopenia. | 10-21-2010 |
20110015126 | Compositions and Methods For Inducing Apoptosis In Tumor Cells - A method is described for using an E-domain peptide for the induction of apoptosis in a cancer cells. In particular, the invention relates to methods for using a-type E-domain peptide from trout IGF and/or a b-type E-domain peptide from human IGF for the induction of apoptosis in a broad spectrum of cancer cells. The peptide species can be a homologue of the E-domain of IGF-1 or a fusion protein comprising the E-domain of IGF-1. It can be administered to one or more cancer cells alone or in a pharmaceutically acceptable composition. | 01-20-2011 |
20110144014 | CYTOKINE RECEPTOR MODULATORS AND USES THEREOF - The present invention relates to cytokine receptor-binding compounds, such as non-competitive VEGF receptor, IL-1 receptor, IL-4 receptor, or IGF-1 receptor-binding peptides and petidomimetic antagonists, and therapeutic uses of such compounds. The compounds of the present invention may be used in the treatment of cytokine-associated diseases such as proliferative disorders (for example, colon, breast, prostate, and lung cancer), abnormal neovascularization and angiogenesis, age-related macular degeneration, and proliferative and/or inflammatory skin disorders such as psoriasis. | 06-16-2011 |
20110152187 | INSULIN-LIKE GROWTH FACTOR FUSION PROTEINS - This disclosure relates to insulin-like growth factor fusion polypeptides; nucleic acid molecules encoding said polypeptides and methods of treatment that use said polypeptides. | 06-23-2011 |
20110218145 | ANTIBODIES TO MODIFIED HUMAN IGF-1/E PEPTIDES - High-specificity antibodies can distinguish between modified (e.g, hIGF-1/Ea 3mut) and endogenous wild-type human IGF-1 proteins. These antibodies have little or no cross-reactivity with hIGF-1 or hIGF-2. They also have little or no cross-reactivity with rodent IGF-1 or IGF-2. The antibodies can be used in pharmacokinetic (PK)/pharamcodynamic (PD) assessments of IGF-1/E peptides that have been administered to humans or animals. A sandwich ELISA assay, using the antibody of the invention as a capture antibody, can quantify the mutant IGF-1/E proteins in samples. | 09-08-2011 |
20120021983 | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND PROGNOSIS OF CANCER AND PROGRESSION, AND FOR SCREENING ANTI-CANCER AGENTS - MicroRNA (miRNA) profiling of cells showed unique miRNA signatures for each of three Akt isoforms. Among differentially regulated miRNA species, the miR-200 family was downregulated in Akt2-expressing cells. Akt1 knockdown inhibited expression of miR-200 and promoted TGFβ-induced epithelial-mesenchymal-transition (EMT) and a stem cell like phenotype. Carcinomas developing in MMTV-cErb2/Akt1 | 01-26-2012 |
20120129772 | SOLUBLE IGF RECEPTORS AS ANTI-ANGIOGENIC AGENTS - There is disclosed a method of inhibiting angiogenesis in a patient having an angiogenic associated disorder comprising administering to said patient a therapeutically effective amount of a soluble IGF-IR protein. The use of such soluble IGF-IR protein for inhibiting angiogenesis in a patient is also disclosed. | 05-24-2012 |
20130143810 | Virally-Inactivated Growth Factors-Containing Platelet Lysate Depleted of PDGF and VEGF and Preparation Method Thereof - The invention concerns human platelet extracts rich in growth factors (PGF) for wound healing and stem cell expansion. Accordingly the subject invention relates to a virally-inactivated growth factors-containing platelet lysate depleted of PDGF and VEGF, which is preferably enriched in TGF, IGF and EGF-rich. The present invention further concerns a method for obtaining a platelet lysate comprising the steps of contacting a starting platelet concentrate with a solvent and/or a detergent, incubating the starting platelet concentrate with the solvent and/or detergent for a period of at least 5 minutes to 6 hours, at a pH maintained in a range from about 6.0 to about 9.0, and at a temperature within the range of from 2° C. to 50° C., optionally removing the solvent and/or the detergent by oil extraction and obtaining an aqueous protein phase, and incubating the solvent and/or detergent-treated platelet concentrate or the aqueous protein phase with charcoal. | 06-06-2013 |
20130184206 | Selective androgen receptor modulators (SARMs) and uses thereof - Provided herein are compounds that bind to androgen receptors and/or modulate activity of androgen receptors. Also provided are methods for making and using such compounds. Also provided are compositions including such compounds and methods for making and using such compositions. | 07-18-2013 |
20130252888 | USE OF IMP3 AS A PROGNOSTIC MARKER FOR CANCER - Provided herein are methods and compositions for the prognostic evaluation of a patient suspected of having, or having, cancer by assessing the expression of IMP3 in a biological sample of a patient. Methods can be used at the time of initial diagnosis of malignant tumors to identify a group of patients with a high potential to develop progression or metastasis later. Therefore, methods not only are able to provide very useful prognostic information for patients but also can help clinicians to select a candidate patient likely to benefit from early and aggressive cancer therapy. Methods and compositions for the treatment of cancer associated with expression of IMP3 are also provided. | 09-26-2013 |
20150337375 | BIOMARKERS FOR CHRONIC TRAUMATIC ENCEPHALOPATHY - This invention relates to the field of screening for, identifying, diagnosing, and prognosing chronic traumatic encephalopathy (CTE). Specifically, this invention provides various biomarkers for this disease, and methods of using these biomarkers to correctly diagnose, prognose and predict those individuals who would develop CTE after suffering from mild traumatic brain injury. The invention also provides targets for drug development and basic research for CTE and preventative and therapeutic agents for CTE. | 11-26-2015 |
514800600 | Insulin-like growth factor 1 (IGF-1) or derivative | 49 |
20100317579 | CONTROLLED RELEASE FORMULATIONS OF OCTREOTIDE - A formulation of octreotide or pharmaceutically acceptable salts thereof, which provides controlled release of a therapeutically effective amount of octreotide for a period of at least about two months. Methods of treating acromegaly, decreasing growth hormone, decreasing IGF-1, and treating conditions associated with carcinoid tumors and VIPomas by administering a controlled release formulation of octreotide are provided herein. | 12-16-2010 |
20110003746 | Protein variants - IGF-I variants having an alanine, glycine, or serine amino acid residue at position 16, 25, 49 or at positions 3 and 49 of native-sequence IGF-I are provided that are useful to treat a disorder characterized by dysregulation of the GH/IGF axis in a mammal, such as a renal disorder. | 01-06-2011 |
20110009317 | CONJUGATES OF INSULIN-LIKE GROWTH FACTOR-1 AND POLY(ETHYLENE GLYCOL) - A conjugate consisting of an insulin-like growth factor-1 (IGF-I) variant and one or two poly(ethylene glycol) group(s), characterized in that said IGF-I variant has an amino acid alteration at up to three amino acid positions 27, 37, 65, 68 of the wild-type IGF-I amino acid sequence so that one or two of said amino acids is/are lysine and amino acid 27 is a polar amino acid but not lysine, is conjugated via the primary amino group(s) of said lysine(s) and said poly(ethylene glycol) group(s) have an overall molecular weight of from 20 to 100 kDa is disclosed. This conjugate is useful for the treatment of neurodegenerative disorders like Alzheimer's Disease. | 01-13-2011 |
20110009318 | Transdermal Compositions and Methods for Treatment of Fibromyalgia and Chronic Fatigue Syndrome - Compositions and methods for alleviating the symptoms associated with chronic fatigue syndrome and fibromyalgia syndrome are provided. The compositions are based on use of a transdermal gel formulation delivery system for androgens, either alone or in combination with other hormones. | 01-13-2011 |
20110065637 | Method to reduce SLOSH energy absorption and its damaging effects through the reduction of inelastic collisions in an organism - A first embodiment can be a method to reduce SLOSH energy absorption within an organism by reducing the inelastic collisions. A fluid containing organism can utilize an embodiment of the method wherein one or more of reversibly increasing pressure within the organs or cells, reversibly increasing the volume within the organs or cells, reversibly altering vascular, molecular, or cell wall stiffness, or reversibly altering vascular, molecular, or cell wall configuration within said organism may reduce these collisions. | 03-17-2011 |
20110152188 | PHARMACEUTICAL COMPOSITIONS OF IGF/I PROTEINS - The present invention relates to a pharmaceutical composition, comprising an Insulin-like growth factor I (IGF-I) protein as active pharmaceutical ingredient (API), a tonicity agent and a buffer. This composition may be administered as injection or infusion and is especially useful for the treatment, prevention and/or delay of progression of neurodegenerative disorders, in particular Alzheimer's Disease (AD), a motor neuron disease (MND), in particular amyotrophic lateral sclerosis (ALS) or Spinal Muscular Atrophy (SMA) or a Muscular Dystrophy (MD), in particular Duchenne Muscular Dystrophy (DMD) or Myotonic Dystrophy (MMD). | 06-23-2011 |
20110183903 | USE OF PEGylated IGF-I VARIANTS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS - The present invention relates to a pharmaceutical composition containing a PEGylated IGF-I variant derived from the wild-type human IGF-I amino acid sequence where one or two of the lysine amino acids at positions 27, 65, and 68 are altered to be a polar amino acid other than lysine and where the PEG is attached to at least one lysine residue. The invention also relates to methods for the treatment, prevention and/or delay of progression of neuromuscular disorders, in particular amyotrophic lateral sclerosis (ALS) by administering a therapeutically effective amount of the pharmaceutical composition of the invention. | 07-28-2011 |
20120088721 | Cartilage Repair - This invention relates to compositions, methods of preparation thereof, and use thereof for cartilage repair. | 04-12-2012 |
20120135926 | PEPTIDES FOR INHIBITING IGF-1 - The invention relates to peptides useful for inhibiting IGF-1 activity and their use as agents for inhibition of in vitrocell proliferation and for treatment of various diseases. | 05-31-2012 |
20120149640 | PEPTIDES MODULATING THE ACTIVITY OF IGF-1 AND THE APPLICATIONS OF SAID PEPTIDES - The invention relates to peptides for modulate IGF-1 activity, a pharmaceutical composition comprising them as well as their applications as medicinal products and cell proliferation modulating agents in vitro. | 06-14-2012 |
20120149641 | Methods and Compositions for Regenerating Articular Cartilage - Methods and compositions are described to regenerate cartilage in a partial thickness defect or area of reduced volume of articular cartilage comprising an infiltration suppressor agent and a columnar growth promoting agent. | 06-14-2012 |
20120190620 | METHODS TO IDENTIFY TARGETS AND MOLECULES REGULATING PURINOSOMES AND THEIR USES - The present invention discloses methods to identify targets, pathways and molecules regulating purinosomes and their uses for treating pathophysiological disorders associated with purinosomes. Disclosed are methods related to both label-free cellular assays and fluorescence imaging to confirm the regulatory roles of various targets and molecules in purinosome dynamics. Disclosed are methods to classify molecules and the uses of these molecules for different indications. Specifically, the purinosome-disrupting molecules can be used for improved prevention and treatment of cancer development. | 07-26-2012 |
20120232009 | Methods for Treatment of Insulin-Like Growth Factor-1 Deficiency - The present invention provides a method comprising administering to a patient suffering from an endocrine disorder characterized by partial endogenous growth hormone activity or signaling an amount of insulin-like growth factor-1 (IGF-1) and an amount of growth hormone (GH) that in combination are effective to improve growth or metabolism in the patient, where the patient receives IGF-1 in a single daily administration and receives GH in a single daily administration, and where the single administrations are administered to the patient substantially contemporaneously each day. | 09-13-2012 |
20120245088 | COMPOSITIONS COMPRISING IGF1 AGONISTS AND USES THEREOF - Pharmaceutical compositions and methods for improving functional capacity of tissues and organs in both healthy and pathologic disease states for: reducing unwanted cosmetic effects of aging on the skin to reduce wrinkles, to increase collagen and water content, thicken and increase skin volume and to maintain a youthful appearance to age and sun damaged skin, to treat diseases of skin and tissues caused by ischemia of venous congestion and arterial insufficiency, to accelerate healing of tendons, ligaments, joints, cartilage, nerves, bones or neuromuscular injuries or diseases, to improve and restore the functional capacity of specific tissues and organs of the body, and to treat hair loss comprising an effective amount of an insulin-like growth factor selected from the group consisting of IGF-1 (Somatmedin-C) and analogue LR3 IGF1 in admixture with a pharmaceutically-acceptable diluent or carrier. | 09-27-2012 |
20120264689 | METHODS AND COMPOSITIONS FOR SKIN REGENERATION - Compositions and methods for inducing tissue differentiation and growth within a localized area of application in humans or other animals are provided. Compositions comprising a biological or pharmacologically active agent such as Insulin-like Growth Factor-1 (IGF-1) and sustained-release nanoparticle formulations comprising IGF-1 and a matrix forming component such as hyaluronan for use in skin repair and regeneration are provided. Nanoparticles of the invention activate endogenous stem cells in the local area of administration to produce new dermal cells and tissues. | 10-18-2012 |
20120270782 | FORMULATION FOR HGH AND RHIGF-1 COMBINATION - The present invention relates to pharmaceutical compositions. More particularly, the invention relates to formulations of growth hormone (GH) and insulin-like growth factor (IGF-1) combination compositions which provide stable pharmaceutical compositions without aggregation formation at a desirable pH, and to processes of preparation thereof. | 10-25-2012 |
20120283185 | FOOD COMPOSITION AND METHOD OF USING SAME - The present invention relates to a food composition preferably for changing body composition and/or physical work capacity. The invention further provides a method of improving body composition and/or physical work capacity. In an aspect of the present invention there is provided a food composition for use in changing the body composition and/or physical work capacity, said food composition including colostrum. In a preferred aspect there is provided a food composition for use in changing the body composition and/or physical factors maintained therein following fractionation of the colostrum. The food composition may additionally include casein. Preferably the casein is colostrum-derived and is maintained in the colostrum fraction following processing of the colostrum. | 11-08-2012 |
20120283186 | THERAPEUTIC AGENT DELIVERY APPARATUS AND PROCESS - A method and device to deliver medication in a liquid, gel or suspension formulation to a plurality of adjacent tissue sites of a mammal, the device comprising a plurality of tissue-engaging members for receiving the medication and operably engageable with the plurality of tissue sites; means for supplying the tissue-engaging members with the formulation, and to temporarily sustain and control the rate of therapeutic agent/unit of time and preferably to sustain these controlled delivery rates over extended periods of time to enhance the local therapeutic effect of these therapeutic agents and to reduce the systemic toxicity and reduce unwanted side effects. | 11-08-2012 |
20120309679 | IGF-I POLY (ETHYLENE GLYCOL) CONJUGATES - Herein is reported a method for producing of a polypeptide conjugated to one poly (ethylene glycol) comprising a) providing a nucleic acid encoding an expression construct comprising in 5′ to 3′ direction a nucleic acid encoding a polypeptide, and a nucleic acid encoding a trypsin site of SEQ ID NO: 01, b) expressing the nucleic acid of a) in a cell and recovering the expression construct from the cell and/or the cultivation medium, c) providing a target peptide with an amino acid sequence of SEQ ID NO: 02 covalently conjugated to a poly (ethylene glycol) at the C-terminal lysine residue, d) incubating the expression construct and the target peptide with the trypsin mutant D189K, K60E, N143H, E151H, and e) recovering and thereby producing the polypeptide conjugated to one poly (ethylene glycol) from the incubation mixture. | 12-06-2012 |
20120322732 | CONJUGATES OF INSULIN-LIKE GROWTH FACTOR-1 AND POLY(ETHYLENE GLYCOL) - A conjugate consisting of an insulin-like growth factor-1 (IGF-I) variant and one or two poly(ethylene glycol) group(s), characterized in that said IGF-I variant has an amino acid alteration at up to three amino acid positions 27, 37, 65, 68 of the wild-type IGF-I amino acid sequence so that one or two of said amino acids is/are lysine and amino acid 27 is a polar amino acid but not lysine, is conjugated via the primary amino group(s) of said lysine(s) and said poly(ethylene glycol) group(s) have an overall molecular weight of from 20 to 100 kDa is disclosed. This conjugate is useful for the treatment of neurodegenerative disorders like Alzheimer's Disease. | 12-20-2012 |
20130059779 | Stabilized Insulin-like Growth Factor Polypeptides - The invention relates to stabilized polypeptides having an IGF-1 sequence and an Ea peptide sequence, where the natural physiological cleavage of the Ea peptide from the IGF-1 is prevented. | 03-07-2013 |
20130065831 | METHOD FOR THE PRODUCTION OF CONJUGATES OF INSULIN-LIKE GROWTH FACTOR-1 AND POLY(ETHYLENE GLYCOL) - The present invention relates to a fusion protein comprising IGF-I or an IGF-I variant N-terminally linked to the C-terminus of a propeptide. The invention relates also to a method involving the use of the aforementioned fusion protein in the production of a lysine-PEGylated IGF-I or IGF-I variant. The method comprises the steps of cultivating a prokaryotic host cell comprising an expression vector containing a nucleic acid encoding the fusion protein and causing the cell to express the fusion protein, recovering and PEGylating said fusion protein, cleaving said PEGylated fusion protein with IgA protease, and recovering lysine-PEGylated IGF-I or IGF-I variant. The invention relates also to a lysine-PEGylated IGF-I or IGF-I variant produced using the above method. In addition, the invention relates to a method for treating a neurodegenerative disorders like Alzheimer's Disease using the lysine-PEGylated IGF-I or IGF-I variant and a composition comprising the lysine-PEGylated IGF-I or IGF-I variant. | 03-14-2013 |
20130172253 | METHOD OF DIAGNOSING AND TREATING OXIDATIVE STRESS-IMPAIRED WOUND HEALING - The method of diagnosing and treating oxidative stress-impaired wound healing allows a practitioner to identify a subject at risk of having impaired wound healing by identifying the sensitivity of that patient to IGF-1. A finding of IGF-1 resistance, either systemically or at the site of an already existing wound, indicates an increased likelihood that the wound will have difficulty healing. In addition, identifying IGF-1 resistance by this method indicates that treatment of a wound with a combination of an antioxidant, IGF-1 and IGFBP-1 will provide optimal healing. | 07-04-2013 |
20130184207 | LONG-ACTING POLYPEPTIDES AND METHODS OF PRODUCING AND ADMINISTERING SAME - A polypeptide and polynucleotides comprising at least two carboxy-terminal peptides (CTP) of chorionic gonadotrophin attached to a non-human peptide-of-interest are disclosed. Pharmaceutical compositions comprising the non-human polypeptides and polynucleotides of the invention and methods of using both human and non-human polypeptides and polynucleotides are also disclosed. | 07-18-2013 |
20130217623 | CONJUGATES OF INSULIN-LIKE GROWTH FACTOR-1 AND POLY(ETHYLENE GLYCOL) - A conjugate consisting of an insulin-like growth factor-1 (IGF-I) variant and one or two poly(ethylene glycol) group(s), characterized in that said IGF-I variant has an amino acid alteration at up to three amino acid positions 27, 37, 65, 68 of the wild-type IGF-I amino acid sequence so that one or two of said amino acids is/are lysine and amino acid 27 is a polar amino acid but not lysine, is conjugated via the primary amino group(s) of said lysine(s) and said poly(ethylene glycol) group(s) have an overall molecular weight of from 20 to 100 kDa is disclosed. This conjugate is useful for the treatment of neurodegenerative disorders like Alzheimer's Disease. | 08-22-2013 |
20130310316 | METHOD AND PRODUCT FOR TREATMENT AND/OR PREVENTION OF COMPLICATIONS OF PREMATURITY - The present invention relates to a composition comprising Insulin Growth Factor I (IGF-I) or an analog thereof in combination with Insulin Growth Factor Binding Protein (IGFBP) or an analog thereof, said combination having a molar ratio of IGF-I to IGFBP being lower than equimolar, preferably in the range from 1:20 to 1:3.33, for use in the treatment of a patient suffering from complications of preterm birth, very preterm birth and/or extremely preterm birth, as well as a method for treating a patient suffering from complications of preterm birth, very preterm birth and/or extremely preterm birth. | 11-21-2013 |
20130345132 | USE OF HGH FOR THE TREATMENT OF SMALL FOR GESTATIONAL AGE INFANTS UNDER TWO YEARS OF AGE - The invention provides a method and a composition for the treatment of infants age less than 2.5 years old defined as small for gestational age (SGA), including the use of hGH or any compound that increases blood levels of hGH or of IGF-I. Early use of the composition prevents the irreversible neurological and psychological damage of the children. | 12-26-2013 |
20140073567 | USE OF PEGYLATED IGF-1 VARIANTS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS - The present invention relates to a pharmaceutical composition containing a PEGylated IGF-I variant derived from the wild-type human IGF-I amino acid sequence where one or two of the lysine amino acids at positions 27, 65, and 68 are altered to be a polar amino acid other than lysine and where the PEG is attached to at least one lysine residue. The invention also relates to methods for the treatment, prevention and/or delay of progression of neuromuscular disorders, in particular amyotrophic lateral sclerosis (ALS) by administering a therapeutically effective amount of the pharmaceutical composition of the invention. | 03-13-2014 |
20140113860 | LONG-ACTING POLYPEPTIDES AND METHODS OF PRODUCING AND ADMINISTERING SAME - A polypeptide and polynucleotides comprising at least two carboxy-terminal peptides (CTP) of chorionic gonadotrophin attached to a non-human peptide-of-interest are disclosed. Pharmaceutical compositions comprising the non-human polypeptides and polynucleotides of the invention and methods of using both human and non-human polypeptides and polynucleotides are also disclosed. | 04-24-2014 |
20140171366 | Compounds and methods for treating cancer - The present invention provides a method of treating cancer involving administering an insulin-like growth factor-1 receptor (IGF-1 receptor) agonist and an anti-cancer chemotherapeutic agent. Also provided are compounds for treating cancer comprising an IGF-1-receptor ligand coupled to an anti-cancer chemotherapeutic agent. Also provided are compounds for treating cancer comprising an insulin-receptor ligand coupled to an anti-cancer chemotherapeutic agent. | 06-19-2014 |
20140213517 | Thermoresponsive, Biodegradable, Elastomeric Material and Uses Therefor - Provided are novel biocompatible copolymers and compositions comprising the copolymers. The copolymers are non-toxic and typically have an LCST below 37° C. Compositions comprising the copolymers can be used for wound treatment, as a cellular growth matrix or niche and for injection into cardiac tissue to repair and mechanically support damaged tissue. The copolymers comprise numerous ester linkages so that the copolymers are erodeable in situ. Degradation products of the copolymers are soluble and non-toxic. The copolymers can be amine-reactive so that they can conjugate with proteins, such as collagen. Active ingredients, such as drugs, can be incorporated into compositions comprising the copolymers. | 07-31-2014 |
20140243265 | ANTIBODIES TO MODIFIED HUMAN IGF-1/E PEPTIDES - High-specificity antibodies can distinguish between modified (e.g, hIGF-1/Ea 3mut) and endogenous wild-type human IGF-1 proteins. These antibodies have little or no cross-reactivity with hIGF-1 or hIGF-2. They also have little or no cross-reactivity with rodent IGF-1 or IGF-2. The antibodies can be used in pharmacokinetic (PK)/pharamcodynamic (PD) assessments of IGF-1/E peptides that have been administered to humans or animals. A sandwich ELISA assay, using the antibody of the invention as a capture antibody, can quantify the mutant IGF-1/E proteins in samples. | 08-28-2014 |
20140315806 | VETERINARY DECORIN COMPOSITIONS AND USE THEREOF - The present invention relates to veterinary decorin compositions and methods of their production. | 10-23-2014 |
20140349931 | DETECTION AND TREATMENT OF BREAST CANCER - The present invention describes methods for determining the risk that a breast precursor lesion will progress to invasive breast cancer and/or the risk of recurrent non-invasive disease in a patient, comprising detecting the presence and/or level of PAPPA and/or PAPPA functional activity in a breast tissue sample obtained from the patient, wherein if PAPPA is not present, or is present at a reduced amount compared to a control, there is the risk of progression to invasive cancer and/or the risk or recurrent disease. | 11-27-2014 |
20140357558 | COMPOSITIONS AND METHODS FOR TREATMENT OF SPINAL MUSCULAR ATROPHY - Disclosed herein are compounds, compositions and methods for treatment of diseases and disorders, including spinal muscular atrophy. | 12-04-2014 |
20140371144 | LONG-ACTING GROWTH HORMONE AND METHODS OF PRODUCING SAME - Use of a growth hormone protein and polynucleotides encoding same comprising an amino-terminal carboxy-terminal peptide (CTP) of chorionic gonadotrophin and two carboxy-terminal chorionic gonadotrophin CTPs attached to the growth hormone in methods of inducing weight loss or body fat reduction, methods of increasing insulin-like growth factor (IGF-1) levels, and methods of reducing the dosing frequency of a growth hormone in a human subject are disclosed. Pharmaceutical compositions comprising the growth hormone and polynucleotides encoding the growth hormone of the invention and methods of using same are also disclosed. | 12-18-2014 |
20140378379 | COMBINATION THERAPY - The present disclosure relates to a method for treatment or prevention of diseases have an increased level of insulin-like growth factor I (IGF-I). The method comprises administration of a growth hormone (GH) variant having antagonistic activity in combination with an oligonucleotide targeted to growth hormone receptor (GHR) to a subject in need. | 12-25-2014 |
20150038413 | LONG-ACTING POLYPEPTIDES AND METHODS OF PRODUCING AND ADMINISTERING SAME - A polypeptide and polynucleotides comprising at least two carboxy-terminal peptides (CTP) of chorionic gonadotrophin attached to a non-human peptide-of-interest are disclosed. Pharmaceutical compositions comprising the non-human polypeptides and polynucleotides of the invention and methods of using both human and non-human polypeptides and polynucleotides are also disclosed. | 02-05-2015 |
20150099699 | CONJUGATES OF INSULIN-LIKE GROWTH FACTOR-1 AND POLY(ETHYLENE GLYCOL) - A conjugate consisting of an insulin-like growth factor-1 (IGF-I) variant and one or two poly(ethylene glycol) group(s), characterized in that said IGF-I variant has an amino acid alteration at up to three amino acid positions 27, 37, 65, 68 of the wild-type IGF-I amino acid sequence so that one or two of said amino acids is/are lysine and amino acid 27 is a polar amino acid but not lysine, is conjugated via the primary amino group(s) of said lysine(s) and said poly(ethylene glycol) group(s) have an overall molecular weight of from 20 to 100 kDa is disclosed. This conjugate is useful for the treatment of neurodegenerative disorders like Alzheimer's Disease. | 04-09-2015 |
20150099700 | METHODS FOR DETECTING PROGENITOR CELLS AND USES THEREOF - Diagnostic and therapeutic methods pertaining to diseases and disorders of the breast, uterus and ovary are encompassed herein. More particularly, diagnostic methods for early detection of progenitor cells of breast, uterine, and ovarian cancers are described herein. The identification of markers for these cancer predisposing progenitor cells, which co-express the progesterone receptor (PR) and p63, provides tools and methods of use thereof that facilitate early detection of increased frequency of PR/p63 double positive (PR/p63+) progenitor cells in asymptomatic patients and thus, early detection of increased cancer risk in such patients and assessment, diagnostic stratification, and evaluation of therapeutic intervention in symptomatic patients. Therapeutic methods are also encompassed herein, which include detection of PR/p63+ progenitor cells in a patient, wherein detection of increased frequency of PR/p63+ progenitor cells provides information on which basis a determination of therapeutic regimen or an assessment of an ongoing therapeutic regimen can be made. | 04-09-2015 |
20150119327 | DRUG SCREENING PLATFORM FOR RETT SYNDROME - The invention provides a method for restoring a neural cell having a deficiency or alteration in glutamatergic pathway affecting neuron and/or glial function comprising contacting the cell with a NMDA receptor antagonist(s) and/or modulator(s) of a glutamatergic pathway, thereby restoring the neural cell having a deficiency or alteration in glutamatergic pathways affecting neuron and/or glial function. | 04-30-2015 |
20150133380 | METHODS FOR TREATING DISEASES WITH PEPTIDES THAT INHIBIT IGF-1 - The invention relates to peptides useful for inhibiting IGF-1 activity and their use as agents for inhibition of in vitro cell proliferation and for treatment of various diseases. | 05-14-2015 |
20150306171 | THERAPEUTIC AGENT COMPOSITION AND METHOD OF USE - The invention relates to the use of cyclic Prolyl Glycine (“cyclic PG” or “cPG”) and analogs and mimetics thereof, as neuroprotective agents for the treatment and or prevention of neurological disorders including but not limited to cerebral ischemia or cerebral infarction resulting from a range of phenomena, such as thromboembolic or hemorrhagic stroke, cerebral basospasms, hypoglycemia, cardiac arrest, status epilepticus, perinatal asphyxia, anoxia such as from drowning, pulmonary surgery, and cerebral trauma, as well as to the treatment and prevention of chronic neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, and Huntington's disease, and as anticonvulsants. | 10-29-2015 |
20150329614 | STABILIZED INSULIN-LIKE GROWTH FACTOR POLYPEPTIDES - This invention is in the field of IGF-1 modifications. In particular, it relates to modified IGF-polypeptides and modified IGF-1 precursor polypeptides wherein the cleavage of E-peptide is prevented. The invention also relates to the use of such polypeptides for treating muscle diseases and disorders. | 11-19-2015 |
20160058878 | Process for preparing a composition of pegylated proteins - This invention is in the field of protein pegylation. In particular, it relates to a method for pegylating therapeutic proteins. The invention also relates to the use of such pegylated therapeutic polypeptides for treating muscle diseases and disorders. | 03-03-2016 |
20160129089 | COMBINATION THERAPY - The present disclosure relates to a method for treatment or prevention of diseases have an increased level of insulin-like growth factor I (IGF-I). The method comprises administration of a Somatostatin analogs having agonistic activity in combination with an oligonucleotide targeted to growth hormone receptor (GHR) to a subject in need. | 05-12-2016 |
20160143999 | COMBINATION THERAPY - The present disclosure relates to a method for treatment or prevention of diseases have an increased level of insulin-like growth factor I (IGF-I). The method comprises administration of a growth hormone (GH) variant having antagonistic activity in combination with an oligonucleotide targeted to growth hormone receptor (GHR) to a subject in need. | 05-26-2016 |
20180021408 | Fusion Proteins Containing Insulin-Like Growth Factor-1 and Epidermal Growth Factor and Variants Thereof and Uses Thereof | 01-25-2018 |
20180021410 | METHODS FOR INCREASING PERFORMANCE CHARACTERISTICS IN OFFSPRING | 01-25-2018 |
514800700 | Insulin-like growth factor binding protein (IGFBP) or derivative | 5 |
20110207665 | METHOD OF REGULATING PROLIFERATION AND DIFFERENTIATION OF KERATINOCYES - Provided are methods of regulating keratinocytes proliferation and differentiation by subjecting keratinocytes to an agent capable of modulating activity or expression of IGFBP7, thereby regulating keratinocytes proliferation and differentiation. Also provided are methods of treating pathologies characterized by hyperproliferative keratinocytes by administering IGFBP7 polypeptide or a polynucleotide encoding IGFBP7 polypeptide to a subject. | 08-25-2011 |
20120329712 | Induction of Differential Stress Resistance and Uses Thereof - This invention relates to methods of inducing differential stress resistance in a subject with cancer by starving the subject for a short term, administering a cell growth inhibitor to the subject, or reducing the caloric or glucose intake by the subject. The induced differential stress resistance results in improved resistance to cytotoxicity in normal cells, which, in turn, reduces cytotoxic side-effects due to chemotherapy, as well as improved effectiveness of chemotherapeutic agents. | 12-27-2012 |
20130225491 | Methods and Kits for Treating Disease By Administering Insulin-Like Growth Factor Binding Protein-2 - The present invention is directed to methods of treating Type 1-diabetes by administering a therapeutically effective amount of an Insulin-like Growth Factor-binding protein-2. The present invention is also directed to methods treating Type 2 diabetes by administering a therapeutically effective amount of Insulin-like Growth Factor-binding protein-2. The present invention is further directed to methods treating insulin resistance by administering a therapeutically effective amount of Insulin-like Growth Factor-binding protein-2. The present invention is directed to methods of treating hepatic steatosis by administering a therapeutically effective amount of an Insulin-like Growth Factor-binding protein-2. The present invention is also directed to methods lowering blood glucose and serum insulin in non-diabetic subjects by administering a therapeutically effective amount of Insulin-like Growth Factor-binding protein-2. | 08-29-2013 |
20130310317 | TARGETED THERAPEUTICS BASED ON ENGINEERED PROTEINS FOR TYROSINE KINASES RECEPTORS, INCLUDING IGF-IR - The present invention provides innovative proteins that bind to insulin-like growth factor-I receptor (IGF-IR), as well as other important proteins. The invention also provides innovative proteins in pharmaceutical preparations and derivatives of such proteins and the uses of same in diagnostic, research and therapeutic applications. The invention further provides cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and vectors comprising the polynucleotides encoding the innovative proteins. | 11-21-2013 |
20140045749 | GROWTH FACTOR COMPLEX - A method is provided for treating a disease or condition characterized by aberrant epithelial cell proliferation and/or migration. One step of the method can include administering to a mammal an agent which disrupts an isolated protein complex including: insulin-like growth factor I (IGF-I); an insulin-like growth factor binding protein (IGFBP) selected from IGFBP-3 and IGFBP-5; and vitronectin; or which prevents formation of the isolated protein complex, to thereby treat the disease or condition in the mammal. The agent is selected from the group consisting a polypeptide that is distinguished from IGF-II by substitution of at least one amino acid residue, wherein the polypeptide disrupts the isolated protein complex. | 02-13-2014 |